期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

治疗2型糖尿病药物研究新进展 被引量：12

Latest Progress of Drugs Used in Type-2 Diabetes Mellitus Treatment
原文传递
导出
摘要 目的介绍近年来应用于2型糖尿病的新型药物GLP-1类似物、DPP-IV阻断剂及作用于ECS的药物。方法归纳总结国外相关文献,介绍其作用机制、临床实践、不良反应、权威使用指南。结果与结论此类药物具有一定应用前景,但仍存在较多问题,需要进一步探讨和研究。 OBJECTIVE To introduce the newest antidiabetic drugs,GLP-1 analogues,DPP-IV inhibitors and drugs which act on ESC.METHODS The latest research reports were reviewed,and those drugs＇ action mechanism,clinical practice,side effects and guideline that expressed by authoritative department were included.RESULTS AND CONCLUSION Those new antidiabetic drugs have hopeful future but there are many problems that need to study and resolve in the future.
作者 盛建民
机构地区 德州学院医学系
出处 《中国现代应用药学》 CAS CSCD 北大核心 2011年第4期311-314,共4页 Chinese Journal of Modern Applied Pharmacy
关键词 2型糖尿病 GLP-1类似物 DPP-IV阻断剂 作用于ECS药物 type-2 diabetes GLP-1 analogues DPP-IV inhibitors drugs act on ECS
分类号 R297.15 [医药卫生—民族医学]
  • 相关文献

参考文献33

  • 1NEUMILLER J J, CAMPBELL R K. Liraglutide: a once-daily incretin mimetic for the treatment of type 2 diabetes mellitus [J]. Ann Pharmacother, 2009, 43 (9): 1433-1444.
  • 2WAUGH N, CUMMINS E, ROYLE P, et al. Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation [J]. Health Technol Assess, 2010, 14 (36): 241-248.
  • 3BUSE J B, KLONOFF D C, NIELSEN L L, et al. Metabolic effects of two years of exenatide treatment on diabetes, obesity and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials [J]. Clin Ther, 2007, 29(1): 139-153.
  • 4BUSE J B, HENRY R R, HAN J, et al. Effects of Exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes [J]. Diabetes Care, 2004, 27(11): 2628-2635.
  • 5DEFRONZO R A, RATNER R E, HAN J, et al. Effects of Exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes [J]. Diabetes Care, 2005, 28(5): 1092-1100.
  • 6Z1NMAN B, HOOGWERF B J, DURAN G S, et al. The effect of adding Exenatide to a tbiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial [J]. Ann Intern Med, 2007, 146(7): 477-485.
  • 7NAUCK M A, DURAN S, KIM D, et al. A comparison of twice-daily Exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study [J]. Diabetologia, 2007, 50(2): 259-267.
  • 8BARNETT A H, BURGER J, JONES D, et al. Tolerability and efficacy of Exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulphonylurea: a multinational, randomized, open-label, two-period, crossover noninferiority trial [J]. Clin Ther, 2007, 29(11): 2333-2348.
  • 9YOON N M, CAVAGHAN M K, BRUNELLE R L, et al. Exenatide added to insulin therapy: a retrospective review of clinical practice over two years in an academic endocrinology outpatient setting [J]. Clin Ther, 2009, 31(7): 1511-1523.
  • 10RUSSELL-JONES D. Molecular, pharmacological and clinical aspects of liraglutide, a once-daily human GLP-1 analogue [J]. Mol Cell Endocrinol, 2009, 297(1/2): 137-140.

同被引文献103

引证文献12

二级引证文献62

中国现代应用药学
2011年 第4期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部